⭐️ Excellent #AACR26 abstract breakdown of 🔑 abstracts for #CommunityOncology by the @OncBrothers
Same topic RMC-9805 · 2 peopleLB407LB337KRAS#COMMUNITYONCOLOGY#CM77T#TRUST#RMC-9805-001#LB407Heat 139 likes0 replies4 reposts
AACR Annual Meeting 2026
April 17–22, 2026 · San Diego · 2418 items
← KRAS / RAS targeting: from platform to Phase 3
RMC-9805
2 people · 2 posts
Records
| Drug / trial | Readout | Setting |
|---|---|---|
| zoldonrasibzoldonrasibRMC-9805 | ORR 52%, DCR 93%, mPFS 11.1 mo; ctDNA clearance 73% | G12D NSCLC · Phase 1 |
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
- Whether zoldonrasib’s response rate stays above 40% once the cohort is past 50 patients.
Other cases in this chapter
- daraxonrasibmOS 13.2 vs 6.7 mo, HR 0.40
- daraxonrasib ± GnPmono ORR 47%; +GnP ORR 55%, DCR 90%
- VS-7375NSCLC ORR 68.8% (n=16); pancreas ORR 58%
- elisrasibG12Ci-naive NSCLC ORR 59.5%; pretreated 32.3%
- RM-055Active in daraxonrasib-resistant and RAS-amplification models
Floor
x.com@Score6060
Bhaarath PG@BhaarathP10039Score6060 Same topic RMC-9805 · 2 peopleSHR-1316III-303RMC-6236PAN-206#ONCOLOGYEVENTS#MEDXHeat 00 likes0 replies0 reposts